newsfilter
← Latest News
GlobeNewswire·

BIODESIX, INC. INVESTIGATION: BDSX Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights

  • Kirby McInerney LLP is investigating potential federal securities law violations & other unlawful business practices by Biodesix, Inc. (NASDAQ: BDSX).
  • On November 5, 2026, Biodesix reported Q3 2026 revenue of $24.0 million, which fell below analyst expectations.
  • The company reduced its full-year 2026 revenue guidance to $101 million-$103 million from a previous range of $108 million-$114 million.
  • CEO Scott Hutton attributed missed results to execution challenges, including fewer sales representatives than planned, unexpected seasonality, & customer delays.
  • Biodesix averaged 101 sales representatives during the quarter due to higher turnover & a hiring pace that failed to keep up with attrition.
  • Following the announcement, Biodesix shares declined by approximately 57%, dropping from $19.84 to $8.53 between November 5 & November 6, 2026.
  • No lawsuit has been filed yet as the investigation remains ongoing to determine if claims can be brought under federal securities laws.
  • Investors are invited to contact Lauren Molinaro at Kirby McInerney LLP to discuss potential claims at no cost.
Company
Kirby McInerney LLP
Keywords
Kirby McInerney LLP, Class Action Lawsuit, Securities Fraud, Investor, Lawsuit, Biodesix, BDSX, Class Action